Tian Yuan's domestic and overseas teams jointly assisted Simcere Pharmaceutical Group Limited (02096.HK) ("Simcere") in completing a share placement of approximately HK$1.567 billion on September 10, 2025. Morgan Stanley acted as the sole overall coordinator, sole global coordinator, sole bookrunner, and placement agent for this share placement.

Founded in 1995, Simcere Pharmaceutical is an innovation- and R&D-driven pharmaceutical company, housing the "National Key Laboratory for Neuro- and Oncology Drug R&D." Simcere focuses on neuroscience, anti-tumor, autoimmune, and anti-infective therapies, while proactively exploring disease areas with significant future clinical needs, committed to its mission of "Born for Patients." Simcere is driven by both independent R&D and collaborative innovation, and has established strategic partnerships with numerous innovative companies and research institutions.

In this placement, Tian Yuan's domestic and overseas teams served as both Chinese and Hong Kong legal counsel for Simcere Pharmaceutical, providing the company with high-quality legal services throughout the entire process, including negotiation, drafting, and revision of transaction documents, preparation of disclosure documents and related applications, regulatory communication, and filing with the China Securities Regulatory Commission. Together, they earned high recognition from the client.

Since Tian Yuan's domestic and international teams jointly assisted Simcere Pharmaceutical in its successful listing on the Main Board of the Hong Kong Stock Exchange on October 27, 2020, they have fully leveraged their advantages in domestic and international collaboration and cooperation, consistently serving as legal counsel to support Simcere Pharmaceutical's long-term development. This includes providing Simcere Pharmaceutical with ongoing compliance legal services for its Hong Kong listing, offering various legal advisory services, assisting in the establishment and revision of its employee incentive plans, and providing legal services in its numerous equity and asset acquisition transactions.

Furthermore, in recent years, Tian Yuan's team has participated in numerous post-IPO financing projects for healthcare companies in the Hong Kong capital market, including but not limited to assisting Hygeia Medical Holdings Limited (06078.HK) in completing a new share placement of approximately HK$800 million and assisting Gushengtang Holdings Limited (02273.HK) in completing a share placement of approximately HK$550 million. Tian Yuan's domestic and international teams have deep expertise in the new economy sector, possessing a top-tier Hong Kong capital market legal team. They have completed numerous pioneering and innovative projects in the fields of healthcare, technology/AI, retail consumption, B2B/SaaS, internet, and entertainment content. Following the introduction of new regulations for overseas listings, they have also completed several China Securities Regulatory Commission (CSRC) filings for share placements and additional share offerings by Hong Kong-listed companies. Leveraging the advantages of domestic and international collaboration, Tian Yuan's domestic and international teams can provide clients with one-stop, comprehensive, efficient, and high-quality legal services in areas such as IPOs for Chinese companies in Hong Kong and subsequent issuances, mergers and acquisitions, privatizations, compliance, and bond transactions related to the Hong Kong capital market. Tian Yuan's domestic and international teams are widely recognized and praised by clients and partner intermediaries, and have repeatedly received awards from various evaluation institutions for their transactions and team performance.

In this transaction, Tian Yuan's domestic team is led by Managing Partner Wu Guanxiong, with assistance from Partner Zhao Wei and lawyers You Yuanyuan and Wen Manying. Tian Yuan's Hong Kong team is led by Managing Partner Nan Li, with assistance from Partner Charles Wang, and lawyers Tiffany Guo and Alan Wang.